Javascript must be enabled to continue!
Clinical trial feasibility assessment and start-up tool (CTFAST).
View through CrossRef
e14089 Background: Selecting the right clinical trials for patients remains a challenging job. The better the match between a clinical trial and the target patient population before conducting a study, the more likely the study will successfully reach the target goal of recruitment. We developed a feasibility assessment scoring system based on our vast clinical research experience, managing multiple sites across a large health system, applicable to oncology as well. Methods: Our feasibility team (FT) is responsible for identifying clinical trials and determining if they are an appropriate match for our institution and unique patient population. Once a potential trial is identified, FT performs a feasibility assessment of the research protocol to determine the resources required to conduct the trial. We developed a Clinical Trial Feasibility Assessment & Start-up Tool (CTFAST) to help sites streamline their feasibility assessments and track their trial through the start-up phase. With CTFAST a feasibility score is generated based on the cumulative value assigned to several items such as: sponsor, study type, pharmacokinetic studies, trial phase, etc. A feasibility scale is assigned as follows: > 25 – Accepted; 15-25 – On Hold; < 15- Rejected. Accepted studies are assigned a color coded priority track (fast, intermediate, routine), that allows team members to prioritize their studies accordingly. Once a study is accepted, the study is processed for enrollment. Results: CTFAST has increased productivity and clinical trial revenues by 40%. CTFAST allows for early identification of bottlenecks in workflow, thereby improving outcomes. By appropriately matching of clinical trials to our site, enrollments increased by 50% with an expanded clinical trial portfolio across 9 different departments. Study start-up times have been reduced to a minimum of 21 days and the use of time & effort has been optimized. Conclusions: CTFAST is replicable across all clinical trial sites and provides an expansive and critical feasibility analysis that is not attainable by traditional querying of investigators and questionnaires. It is an excellent work flow improvement tool as it critically analyzes all aspects of a study, prior to enrollment. When conducting an effective feasibility analysis the clinical trial site can optimize clinical trial outcomes.
American Society of Clinical Oncology (ASCO)
Title: Clinical trial feasibility assessment and start-up tool (CTFAST).
Description:
e14089 Background: Selecting the right clinical trials for patients remains a challenging job.
The better the match between a clinical trial and the target patient population before conducting a study, the more likely the study will successfully reach the target goal of recruitment.
We developed a feasibility assessment scoring system based on our vast clinical research experience, managing multiple sites across a large health system, applicable to oncology as well.
Methods: Our feasibility team (FT) is responsible for identifying clinical trials and determining if they are an appropriate match for our institution and unique patient population.
Once a potential trial is identified, FT performs a feasibility assessment of the research protocol to determine the resources required to conduct the trial.
We developed a Clinical Trial Feasibility Assessment & Start-up Tool (CTFAST) to help sites streamline their feasibility assessments and track their trial through the start-up phase.
With CTFAST a feasibility score is generated based on the cumulative value assigned to several items such as: sponsor, study type, pharmacokinetic studies, trial phase, etc.
A feasibility scale is assigned as follows: > 25 – Accepted; 15-25 – On Hold; < 15- Rejected.
Accepted studies are assigned a color coded priority track (fast, intermediate, routine), that allows team members to prioritize their studies accordingly.
Once a study is accepted, the study is processed for enrollment.
Results: CTFAST has increased productivity and clinical trial revenues by 40%.
CTFAST allows for early identification of bottlenecks in workflow, thereby improving outcomes.
By appropriately matching of clinical trials to our site, enrollments increased by 50% with an expanded clinical trial portfolio across 9 different departments.
Study start-up times have been reduced to a minimum of 21 days and the use of time & effort has been optimized.
Conclusions: CTFAST is replicable across all clinical trial sites and provides an expansive and critical feasibility analysis that is not attainable by traditional querying of investigators and questionnaires.
It is an excellent work flow improvement tool as it critically analyzes all aspects of a study, prior to enrollment.
When conducting an effective feasibility analysis the clinical trial site can optimize clinical trial outcomes.
Related Results
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Optimising tool wear and workpiece condition monitoring via cyber-physical systems for smart manufacturing
Optimising tool wear and workpiece condition monitoring via cyber-physical systems for smart manufacturing
Smart manufacturing has been developed since the introduction of Industry 4.0. It consists of resource sharing and networking, predictive engineering, and material and data analyti...
Abstract 6455: Investigating clinical trial eligibility criteria to improve MatchMiner trial matching
Abstract 6455: Investigating clinical trial eligibility criteria to improve MatchMiner trial matching
Abstract
As the number of precision medicine (PM) trials and the volume of patient genomic data have grown, it has become challenging for clinicians and trial staff ...
Continuity of care: Perspectives of participants, investigators, and healthcare providers after trial completion in South Africa
Continuity of care: Perspectives of participants, investigators, and healthcare providers after trial completion in South Africa
Abstract
Background
Despite decades of updates to frameworks and guidelines for the conduct of clinical trials, what happens to participants when a trial ends rem...
Resiko Sistem Manajemen Kinerja yang Buruk Terhadap Perusahaan Start Up di Indonesia.
Resiko Sistem Manajemen Kinerja yang Buruk Terhadap Perusahaan Start Up di Indonesia.
ABSTRACT
This research aims to evaluate the effect of poor performance management on the failure of start-up companies in Indonesia. Start-ups are businesses engaged in devel...
Abstract P160: MatchMiner: An open-source platform for cancer precision medicine
Abstract P160: MatchMiner: An open-source platform for cancer precision medicine
Abstract
With the advent of next generation sequencing in cancer care, patients’ tumors can be genomically profiled and specific genetic alterations can be targeted ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Behavioural Optimisation To Address Trial Conduct Challenges: Case Study In The UK-REBOA Trial
Behavioural Optimisation To Address Trial Conduct Challenges: Case Study In The UK-REBOA Trial
Abstract
Background: Clinical trials comprise multiple processes at various stages of the trial lifecycle. These processes often involve complex behaviours such as recruiti...

